Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
AstraZeneca PLC (DE:ZEG)
XETRA:ZEG
Holding DE:ZEG?
Track your performance easily
ZEG Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€110.63 - €150.60
Previous Close€146.2
Volume5.51K
Average Volume (3M)20.97K
Market Cap
€226.32B
Enterprise Value€247.26B
Total Cash (Recent Filing)$5.84B
Total Debt (Recent Filing)$28.62B
Price to Earnings (P/E)38.8
Beta0.44
Next Earnings
Jul 25, 2024EPS Estimate
€1.82Last Dividend Ex-Date
Feb 22, 2024Dividend Yield1.86%
Share Statistics
EPS (TTM)3.77
Shares Outstanding1,550,189,338
10 Day Avg. Volume4,075
30 Day Avg. Volume20,969
Standard Deviation0.06
R-Squared0.05
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)-12.86
Price to Sales (P/S)8.53
Price to Cash Flow (P/CF)22.20
P/FCF Ratio27.80
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.58
Enterprise Value/Gross Profit6.59
Enterprise Value/Ebitda27.22
Forecast
1Y Price Target
€154.61Price Target Upside5.75% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering17
AstraZeneca News
PremiumCompany Announcements
AstraZeneca Shares and Voting Rights Update
Bulls Say, Bears Say
Bulls Say
Pipeline PotentialAZN has 5 game-changing Phase III reads for key assets with a total sales potential of around $20 billion.
Revenue And ReratingAZN's new mid-term guide implies 30E revenues 20% above consensus and 30E EBIT at the bottom end of margin guide 10% above consensus.
Sales GrowthSolid key sales drivers (Imfinzi +14%, Farxiga +25%, Fasenra +4%), with a notable acceleration in oral oncology franchises (Tagrisso +6%, Lynparza +5%, Calquence +14%).
Bears Say
Competitive LandscapeJNJ's SubQ Rybrevant represents a more convenient and tolerable offering than IV, likely increasing competition for MARIPOSA in NSCLC.
Financial GuidanceThe company updated currency assumptions, now expecting a mid single digit adverse impact on core EPS.
Regulatory ApprovalThere is no statistically significant overall survival benefit in the intent-to-treat overall population, raising questions about FDA acceptance.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.16% Insiders
14.72% Mutual Funds
8.57% Other Institutional Investors
76.56% Public Companies and
Individual Investors
ZEG FAQ
What was AstraZeneca PLC’s price range in the past 12 months?
AstraZeneca PLC lowest stock price was €110.63 and its highest was €150.60 in the past 12 months.
What is AstraZeneca PLC’s market cap?
Currently, no data Available
When is AstraZeneca PLC’s upcoming earnings report date?
AstraZeneca PLC’s upcoming earnings report date is Jul 25, 2024 which is 45 days ago.
How were AstraZeneca PLC’s earnings last quarter?
AstraZeneca PLC released its earnings results on Apr 25, 2024. The company reported €1.892 earnings per share for the quarter, beating the consensus estimate of €1.755 by €0.137.
Is AstraZeneca PLC overvalued?
According to Wall Street analysts AstraZeneca PLC’s price is currently Undervalued.
Does AstraZeneca PLC pay dividends?
AstraZeneca PLC pays a Annually dividend of €1.83 which represents an annual dividend yield of 1.86%. See more information on AstraZeneca PLC dividends here
What is AstraZeneca PLC’s EPS estimate?
AstraZeneca PLC’s EPS estimate is €1.82.
How many shares outstanding does AstraZeneca PLC have?
AstraZeneca PLC has 1,550,268,100 shares outstanding.
What happened to AstraZeneca PLC’s price movement after its last earnings report?
AstraZeneca PLC reported an EPS of €1.892 in its last earnings report, beating expectations of €1.755. Following the earnings report the stock price went up 6.448%.
Which hedge fund is a major shareholder of AstraZeneca PLC?
Currently, no hedge funds are holding shares in DE:ZEG
---
AstraZeneca Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€154.61 (5.75% Upside)
€154.61 (5.75% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
22.29%
12-Months-Change
Fundamentals
Return on Equity
17.17%
Trailing 12-Months
Asset Growth
3.55%
Trailing 12-Months
Company Description
AstraZeneca PLC
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The company sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
---
ZEG Stock 12 Month Forecast
Average Price Target
€154.61
▲(5.75% Upside)
Technical Analysis
Best Analysts Covering ZEG
1 Year
1 Year Success Rate
30/36 ratings generated profit
1 Year Average Return
+13.89%
reiterated a buy rating 2 months ago
Copying Emily Field's trades and holding each position for 1 Year would result in 83.33% of your transactions generating a profit, with an average return of +13.89% per trade.
---